Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole for obsessive-compulsive symptoms in schizophrenia
IRCT20181001041192N1Phase 3Completed
- Sponsor
- Mazandaran University of Medical Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in schizophrenia and obsessive compulsive disorder (OCD) comparing Aripiprazole with Placebo (2 arms). Primary endpoint: Obsessive-compulsive symptoms in patients. Started Oct 2018; status: completed.
02
Drugs
aripiprazole
03
Conditions
schizophreniaobsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20181001041192N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181001041192N1.